Patient-friendly, non-technical summary of research papers

February 2026 Research Update

This report covers research on Cold agglutinin disease published in PubMed in February 2026. For other months, see all research updates.

Last update: July 13, 2026

At a glance

Care plan changes

Case reports described cold agglutinins appearing during transplant or chemotherapy care and leading teams to adjust the original treatment plan.

Infusion reactions and anemia

Reports linked cold agglutinins with infusion reactions and sudden anemia, including one case where testing showed complement involvement and red blood cell clumping that improved with warming.

Rituximab response (single case)

In one chemotherapy-associated case, rituximab was followed by partial improvement in anemia and hemolysis, but the reports were not focused on testing new treatments for cold agglutinin disease.

What this adds (limited evidence)

Based on two single-patient reports, this month mainly adds clearer examples of how cold agglutinins can complicate transfusions, infusions, and blood counts during other medical treatments rather than defining risk for most people with cold agglutinin disease.

Overview

This month shifted away from testing treatments for cold agglutinin disease and toward describing cold agglutinins as complications during other medical care, with effects that were immediate and clinically disruptive.

Across two single-person reports, the recurring pattern was that cold agglutinins showed up in the middle of a larger care plan and were linked with problems that forced a change in course. In the stem cell transplant setting, cold agglutinins were detected in the donor cell product and the infusion was followed by a reaction and poor early graft function, even though testing showed donor cells were present. In the cancer care setting, cold agglutinin syndrome appeared after paclitaxel chemotherapy and was tied to severe hemolytic anemia.

What became more concrete is the kind of real-world trouble cold agglutinins can cause when they are present: infusion reactions, unstable blood counts, and decisions to adjust or stop an original plan. One report also described a later stem cell boost collected when cold agglutinins were not detected, followed by platelet recovery and less need for transfusions, which raises a focused question about whether donor-related factors in the graft contributed to the earlier problems.

Both reports are early signals, and the main open question is how often these scenarios occur and how directly cold agglutinins drive the complications.

Get the monthly update by email

Subscribe here to receive an email when a new monthly cold agglutinin disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month's new reports were case-based rather than trials of a cold agglutinin disease treatment, and they showed that cold agglutinins can appear as a complication in other medical situations and meaningfully affect how those situations unfold. Across both cases, cold agglutinins were linked to immediate problems (like reactions during an infusion or sudden anemia) and forced changes in the original treatment plan.

In a stem cell transplant case, cold agglutinin antibodies were present in the donor cell product and the infusion was followed by an infusion reaction and poor graft function, even though donor cells were showing up in testing. Later, a CD34-selected stem cell boost from the same donor collected when cold agglutinins were not detected was followed by platelet recovery and transfusion independence, raising the possibility that donor-derived factors in the graft contributed to the early problems. Because this was one person and multiple factors could have played a role, it mainly adds awareness rather than a clear rule for what will happen in other transplants.

In a cancer care case, cold agglutinin syndrome developed after paclitaxel chemotherapy and was linked with severe hemolytic anemia, including a positive blood test showing complement involvement and red cell clumping that improved when warmed. Rituximab (an immune-targeting treatment) was followed by partial improvement in blood counts and hemolysis, but paclitaxel was not restarted and care shifted to other approaches as the cancer progressed. This report highlights that, in rare situations, a drug exposure may be followed by new cold agglutinin-related hemolysis, but a single case cannot prove cause and effect.

For patients and caregivers, this month mainly adds context about where cold agglutinins can show up outside of classic cold agglutinin disease, such as during a stem cell transplant or during chemotherapy. The evidence here is limited to 2 single-patient case reports, so it does not establish how common these events are or predict risk for any individual person. What it does clarify is that when cold agglutinins are present, they can complicate transfusions, infusions, and blood counts, and can lead teams to change the planned course of care.

What remains uncertain is whether the cold agglutinins were the main driver of the complications in these situations or one of several contributors, and whether the same pattern would happen in other patients. These reports matter most as early signals for research and clinical awareness, rather than findings that change routine care for people living with cold agglutinin disease.

Limitations

Both publications were single-patient case reports, so frequency and risk factors cannot be estimated.
The reports cannot prove whether cold agglutinins caused the complications or were one contributor among several.
Follow-up and outcomes were described in narrow clinical situations, which limits how broadly the patterns apply.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.